There are 2949 resources available
Future combinations: Intralesional and other immunotherapy combinations
Presenter: Olivier Michielin
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Slides
Webcast
Future strategies: Sequencing versus combinations in targeted and immune therapy
Presenter: Paolo Ascierto
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Slides
Webcast
Management and learnings from toxicity?
Presenter: Caroline Robert
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Slides
Webcast
Current status of (neo) adjuvant immunotherapy in early stage NSCLC
Presenter: Lizza Hendriks
Session: Breakthroughs in immunotherapy for non-metastatic NSCLC
Resources:
Slides
Webcast
Early stage NSCLC immunotherapy: Which biomarkers matter?
Presenter: Julie Brahmer
Session: Breakthroughs in immunotherapy for non-metastatic NSCLC
Resources:
Slides
Webcast
Unresectable stage III NSCLC: PACIFIC and beyond
Presenter: Maarten Lambrecht
Session: Breakthroughs in immunotherapy for non-metastatic NSCLC
Resources:
Slides
Webcast
Dealing with comorbidities and toxicities in stage I-III NSCLC
Presenter: Dirk De Ruysscher
Session: Breakthroughs in immunotherapy for non-metastatic NSCLC
Resources:
Slides
Webcast
Challenges when using prostate biopsies for genomics
Presenter: Joaquin Mateo
Session: Unlocking precision medicine for metastatic prostate cancer
Resources:
Slides
Webcast
Liquid biopsies: Challenges and opportunities for implementing into clinical practice
Presenter: Gerhardt Attard
Session: Unlocking precision medicine for metastatic prostate cancer
Resources:
Slides
Webcast
Emergence of neuroendocrine prostate cancer and the clinical relevance of tumour evolution
Presenter: Charles Ryan
Session: Unlocking precision medicine for metastatic prostate cancer
Resources:
Slides
Webcast